戈沙妥珠单抗治疗激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌的总生存期(TROPiCS-02):一项随机、开放标签、多中心、3期试验
TROPiCS-02是一项在91个中心开展的随机、开放标签、3期试验,纳入543例经治、内分泌抵抗的HR+/HER2-转移性乳腺癌患者,随机接受戈沙妥珠单抗或化疗(艾立布林、长春瑞滨、卡培他滨或吉西他滨)。中位随访12.5个月,戈沙妥珠单抗组中位总生存期为14.4个月,化疗组为11.2个月(HR 0.79,95%CI 0.65-0.96;p=0.020),且生存获益在Trop-2表达水平各亚组中一致。客观缓解率(21% vs 14%,OR 1.63,p=0.035)、全球健康状况/生活质量恶化时间(4.3个月 vs 3.0个月,HR 0.75,p=0.0059)和疲乏恶化时间(2.2个月 vs 1.4个月,HR 0.73,p=0.0021)均显著改善。作者认为这些数据支持戈沙妥珠单抗作为经治、内分泌抵抗的HR+/HER2-转移性乳腺癌患者的新治疗选择。
要点
- 在经治、内分泌抵抗的HR+/HER2-转移性乳腺癌患者中,戈沙妥珠单抗组中位总生存期14.4个月 vs 化疗组11.2个月(HR 0.79,95%CI 0.65-0.96;p=0.020),绝对获益3.2个月。
- 生存获益在Trop-2表达水平各亚组中一致。
- 客观缓解率戈沙妥珠单抗组21%(57例)vs 化疗组14%(38例)(OR 1.63,95%CI 1.03-2.56;p=0.035)。
- 全球健康状况/生活质量恶化时间戈沙妥珠单抗组4.3个月 vs 化疗组3.0个月(HR 0.75,95%CI 0.61-0.92;p=0.0059);疲乏恶化时间2.2个月 vs 1.4个月(HR 0.73,95%CI 0.60-0.89;p=0.0021)。
- 安全性特征与既往研究一致;1例致命不良事件(中性粒细胞减少性结肠炎所致脓毒性休克)判定与戈沙妥珠单抗治疗相关。
适用人群与场景
- 经组织学确认的HR+且HER2-局部复发不可手术或转移性乳腺癌患者。
- 既往接受过至少一种内分泌治疗、一种紫杉类药物和一种CDK4/6抑制剂(任何治疗阶段),以及针对转移性疾病的两至四种化疗方案。
- 入组于北美(美国和加拿大)和欧洲(比利时、法国、德国、意大利、荷兰、西班牙和英国)的91个中心。
诊断标准与关键阈值
- HR+和HER2-状态需经确认。
- Trop-2表达通过肿瘤组织免疫组化评估,生存获益在Trop-2表达水平各亚组中一致。
处置流程与药物剂量
- 戈沙妥珠单抗组:静脉给药(原文未写明具体剂量、给药频次和疗程)。
- 化疗组:可选择艾立布林、长春瑞滨、卡培他滨或吉西他滨(原文未写明具体剂量和给药方案)。
红旗征与不能漏的情况
- 中性粒细胞减少性结肠炎所致脓毒性休克:1例致命不良事件,判定与戈沙妥珠单抗治疗相关。
研究设计与关键结果
- 研究设计:随机、开放标签、多中心、3期试验,在91个中心开展,2019年5月30日至2021年4月5日随机分配543例患者(戈沙妥珠单抗组272例,化疗组271例),中位随访12.5个月(IQR 6.4-18.8),共发生390例死亡。
- 主要终点无进展生存期(先前已报告,未纳入本次分析);次要终点包括总生存期、客观缓解率和患者报告结局。
- 总生存期:戈沙妥珠单抗组中位14.4个月(95%CI 13.0-15.7)vs 化疗组11.2个月(95%CI 10.1-12.7);HR 0.79(95%CI 0.65-0.96);p=0.020;生存获益在Trop-2表达水平各亚组中一致。
- 客观缓解率:戈沙妥珠单抗组57例(21%)vs 化疗组38例(14%);OR 1.63(95%CI 1.03-2.56);p=0.035。
- 全球健康状况/生活质量恶化时间:戈沙妥珠单抗组中位4.3个月 vs 化疗组3.0个月;HR 0.75(95%CI 0.61-0.92);p=0.0059。
- 疲乏恶化时间:戈沙妥珠单抗组中位2.2个月 vs 化疗组1.4个月;HR 0.73(95%CI 0.60-0.89);p=0.0021。
- 安全性:戈沙妥珠单抗的安全性特征与既往研究一致(包括TROPiCS-02主要分析和ASCENT试验);1例致命不良事件(中性粒细胞减少性结肠炎所致脓毒性休克)判定与戈沙妥珠单抗治疗相关。
证据类型、等级与局限
- 证据类型:随机、开放标签、多中心、3期试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,戈沙妥珠单抗较化疗显示出统计学显著且临床有意义的获益,中位总生存期改善3.2个月,安全性特征可控。
- 作者认为,这些数据支持戈沙妥珠单抗作为经治、内分泌抵抗的HR+/HER2-转移性乳腺癌患者的新治疗选择。
指南或共识出处
- TROPiCS-02试验(ClinicalTrials.gov注册号NCT03901339),由吉利德科学公司资助。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sacituzumab govitecan demonstrated significant progression-free survival benefit over chemotherapy in the phase 3 TROPiCS-02 trial in patients with pretreated, endocrine-resistant hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ and HER2-) metastatic breast cancer with limited treatment options. Here, we report the protocol-specified final analysis of overall survival and endpoints by trophoblast cell-surface antigen 2 (Trop-2) expression and other variables.
METHODS: In this randomised, open-label, multicentre, phase 3 trial, which took place in 91 centres across North America (the USA and Canada) and Europe (Belgium, France, Germany, Italy, the Netherlands, Spain, and the UK), patients were randomly assigned (1:1) to receive sacituzumab govitecan or chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine). Patients had confirmed HR+ and HER2- locally recurrent inoperable or metastatic breast cancer and had received at least one previous endocrine therapy, a taxane, and a CDK4/6 inhibitor in any setting and two to four previous chemotherapy regimens for metastatic disease. The primary endpoint was progression-free survival (previously reported and not included in this analysis), and secondary endpoints included overall survival, objective response rate (ORR), and patient-reported outcomes. Overall survival was assessed using stratified log-rank tests and Cox regression. Trop-2 expression was assessed in tumour tissue by immunohistochemistry. In the statistical testing hierarchy, ORR and patient-reported outcomes were tested sequentially if overall survival was significant. This study is registered with ClinicalTrials.gov, NCT03901339.
FINDINGS: At the data cutoff date of July 1, 2022, 543 of 776 screened patients were randomly assigned between May 30, 2019, and April 5, 2021, with 272 patients in the sacituzumab govitecan group and 271 patients in the chemotherapy group. With a 12·5-month (IQR 6·4-18·8) median follow-up, 390 deaths occurred among 543 patients. Overall survival was significantly improved with sacituzumab govitecan versus chemotherapy (median 14·4 months [95% CI 13·0-15·7] vs 11·2 months [10·1-12·7]; hazard ratio [HR] 0·79, 95% CI 0·65-0·96; p=0·020); survival benefit was consistent across Trop-2 expression-level subgroups. ORR was significantly improved with sacituzumab govitecan compared with chemotherapy (57 [21%] patients vs 38 [14%]; odds ratio 1·63 [95% CI 1·03-2·56]; p=0·035), as was time to deterioration of global health status and quality of life (median 4·3 months vs 3·0 months; HR 0·75 [0·61-0·92]; p=0·0059) and fatigue (median 2·2 months vs 1·4 months; HR 0·73 [0·60-0·89]; p=0·0021). The safety profile of sacituzumab govitecan was consistent with previous studies (including the TROPiCS-02 primary analysis and the ASCENT trial). One fatal adverse event (septic shock caused by neutropenic colitis) was determined to be related to sacituzumab govitecan treatment.
INTERPRETATION: Sacituzumab govitecan demonstrated statistically significant and clinically meaningful benefit over chemotherapy, with a 3·2-month median overall survival improvement and a manageable safety profile. These data support sacituzumab govitecan as a new treatment option for patients with pretreated, endocrine-resistant HR+ and HER2- metastatic breast cancer.
FUNDING: Gilead Sciences.
参考来源
- Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023. PMID: 37633306. doi:10.1016/S0140-6736(23)01245-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。